Acticor Biotech

Acticor Biotech Interest Coverage

Delisted

The Interest Coverage Ratio of Acticor Biotech (ALACT.PA) as of Nov 7, 2026 is -16.34. In the previous year, Interest Coverage Ratio was -19.95 — a change of -18.09% (higher).

Interest Coverage

-16.34

YoY

-18.09%

Last updated:

Interest Coverage Ratio of Acticor Biotech is 2023 -16.34 . Interest Coverage Ratio of Acticor Biotech was 2022 -19.95 . It decreases by -18.09% higher compared to the previous year.

The Acticor Biotech Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2016
-1.08 EUR
Jan 1, 2017
-79.41 EUR
Jan 1, 2018
-551.63 EUR
Jan 1, 2019
-1,033.00 EUR
Jan 1, 2020
-7,576.00 EUR
Jan 1, 2021
-16.54 EUR
Jan 1, 2022
-19.95 EUR
Jan 1, 2023
-16.34 EUR
The Acticor Biotech Interest Coverage history
YEARInterest CoverageYoY
-16.34-18.09%
-19.95+20.64%
-16.54-99.78%
-7,576.00+633.40%
-1,033.00+87.26%
-551.63+594.61%
-79.41+7,279.37%
-1.08-92.47%
-14.29-116.45%
86.86—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acticor Biotech Stock analysis

What does Acticor Biotech do? Acticor Biotech SA develops antithrombotic agents for acute thrombotic diseases, focusing on acute ischemic strokes and pulmonary embolisms. The company has one product, Glenzocimab, in Phase II clinical development, alongside pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN. It collaborates with partnering companies Ouest Valorisation, Genopole, Medicine, and Inserm for research and development. Acticor Biotech SAS is a clinical stage biopharmaceutical company spun off from INSERM, with 24 full-time employees. The firm generates revenue through its research and development activities, leveraging its partnership with INSERM and other institutions. Glenzocimab, its lead product, is in Phase II trials, indicating potential future licensing agreements or sales. The company's pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN represent additional revenue streams once they progress through clinical development. Acticor Biotech targets the biopharmaceutical sector, specifically focusing on thrombotic disease treatments. Its primary customers are pharmaceutical companies seeking to license or co-develop novel antithrombotic therapies. The company's partnerships with Ouest Valorisation, Genopole, Medicine, and Inserm facilitate its R&D efforts and potential commercialization pathways. Acticor Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acticor Biotech stock

Interest Coverage Ratio of Acticor Biotech is -16.34 in 2023.

Interest Coverage Ratio of Acticor Biotech changed from -19.95 to -16.34, representing a -18.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Acticor Biotech since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Acticor Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Acticor Biotech

All Key Metrics — Acticor Biotech